New pharma guidelines: No ghostwriting, more public info

Wall Street Journal Health Blog, October 1, 2009
Clinical trial guidelines from the drug industry trade group PhRMA, go into effect Oct. 1. They include guidelines that basically ban ghostwriting of reports and stipulate that a doctor who has an ownership stake in a drug cannot be a clinical investigator in a trial of that drug. The guidelines are purely voluntary, however.

MOST POPULAR

SPONSORED REPORTS
SPONSORED HEADLINES

SIGN UP

FREE e-Newsletters Join the Council Subscribe to HL magazine

SPONSORSHIP & ADVERTISING

100 Winners Circle Suite 300
Brentwood, TN 37027

800-727-5257

About | Advertise | Terms of Use | Privacy Policy | Reprints/Permissions | Contact
© HealthLeaders Media 2015 a division of BLR All rights reserved.